{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000128","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.460001+00:00","generated_at":"2026-05-17T15:28:12.573451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ivonescimab HARMONi PFS HR 0.52, NMPA approval; Summit Q2 net loss $565.7M","bullets":["HARMONi PFS HR 0.52 (p<0.00001); OS trend HR 0.79 (p=0.057); BLA filing planned.","Ivonescimab monotherapy approved by NMPA for 1L PD-L1 positive advanced NSCLC in China.","HARMONi-6: ivonescimab + chemo superior to tislelizumab + chemo in 1L squamous NSCLC.","Cash & equivalents $297.9M (down from $412.3M); ATM offering of up to $360M.","GAAP net loss $565.7M ($0.76/sh); non-GAAP $86.9M ($0.12/sh); stock modification $466.6M non-cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000128","json":"https://secwatch.observer/filing/0001599298-25-000128.json","markdown":"https://secwatch.observer/filing/0001599298-25-000128.md","text":"https://secwatch.observer/filing/0001599298-25-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000128/0001599298-25-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000128/smmt-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:28:12.573451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}